SynthesisBMC cancer2026
Comparative efficacy and harms of adjuvant whole breast hypofractionation or external beam accelerated partial breast irradiation for treatment of breast cancer: a systematic review.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundWhole breast moderate hypofractionation is recommended for most breast cancer populations to improve survival and reduce recurrence. Whole breast ultra-hypofractionation and external beam accelerated partial breast irradiation (APBI) may reduce toxicity while maintaining benefits.
methodsMEDLINE and Embase searches through March 2024 identified randomized controlled trials (RCTs) evaluating adjuvant external beam hypofractionated radiation therapy for breast cancer. Eligibility and risk of bias (RoB) were assessed by two reviewers and required consensus. For prioritized outcomes (e.g., overall survival, acute toxicity), certainty of evidence was assessed using GRADE.
resultsThirty-nine RCTs compared whole breast moderate hypofractionation vs. conventional radiation (CFRT; k = 25); whole breast ultra-hypofractionation vs. moderate hypofractionation or CFRT (k = 8); or external beam APBI vs. whole breast radiation (k = 6). For all comparisons, there were low RoB, large trials (N > 2,000) with 5-10 year outcomes. Trials on ultra-hypofractionation and APBI focused on early stage cancer, some also including ductal carcinoma in situ (DCIS). High survival (> 90%) and low recurrence were found across all treatments. Moderate hypofractionation probably results in less overall acute toxicity, but makes little to no difference in specific adverse events. No trial on ultra-hypofractionation reported overall toxicity; evidence on acute skin toxicity is very uncertain. APBI probably results in less overall acute toxicity, but may result in more overall late toxicity; evidence was very uncertain or showed no difference for specific events.
conclusionRadiation treatments had similar survival and recurrence. Moderate hypofractionation and APBI result in lower overall acute toxicity, but evidence is lacking for ultra-hypofractionation. For ultra-hypofractionation and APBI, future research is needed to better understand late toxicity outcomes, and whether effects may vary across settings and subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.